Nchi: Australia
Lugha: Kiingereza
Chanzo: Department of Health (Therapeutic Goods Administration)
rivastigmine, Quantity: 18 mg
Arrotex Pharmaceuticals Pty Ltd
Rivastigmine
Drug delivery system, transdermal
Excipient Ingredients: acrylates copolymer; ethyl acetate; hexane; 2-ethylhexyl acrylate; methyl acrylate; acrylic acid; acrylates/ethylhexyl acrylate copolymer; methylated trimethylated silica
Transdermal
7 transdermal drug delivery systems, 30 transdermal drug delivery systems
(S4) Prescription Only Medicine
RIVASTIGMINE APOTEX is indicated for the treatment of patients with mild to moderate dementia of the Alzheimer's type.
Visual Identification: Circular 10cm2 transdermal patch, tri-layer adhesive matrix, translucent white backing film labelled with "Rivastigmine 9.5 mg/24 h"; Container Type: Sachet; Container Material: Other composite material; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius
Licence status A
2016-01-12